These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 18440341

  • 1. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
    Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP.
    Am Heart J; 2008 May; 155(5):910-7. PubMed ID: 18440341
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group.
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E, TIMI Study Group.
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L, IDEA Survey Investigators, Italian Society of Invasive Cardiology.
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ, CREDO Investigators.
    Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial.
    Circulation; 2004 Sep 07; 110(10):1202-8. PubMed ID: 15313956
    [Abstract] [Full Text] [Related]

  • 12. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, CREDO Investigators.
    Am Heart J; 2009 Feb 07; 157(2):369-74. PubMed ID: 19185647
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Sinno MC, Khanal S, Al-Mallah MH, Arida M, Weaver WD.
    Am Heart J; 2007 Apr 07; 153(4):579-86. PubMed ID: 17383297
    [Abstract] [Full Text] [Related]

  • 15. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, Lamy A, Culler S, Caro J, Yusuf S, Weintraub WS, CURE Study Investigators.
    Am Heart J; 2006 Jan 07; 151(1):219-27. PubMed ID: 16368322
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
    Lemesle G, Delhaye C, Sudre A, Broucqsault D, Rosey G, Bauters C, Lablanche JM.
    Am Heart J; 2009 Feb 07; 157(2):375-82. PubMed ID: 19185648
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.
    J Am Coll Cardiol; 2007 Feb 13; 49(6):657-66. PubMed ID: 17291930
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.